Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 Infection

Zeuzem S, Foster GR, Wang S, et al. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 Infection. N Engl J Med [Internet]. 2018;378(4):354-369. https://doi.org/10.1056/nejmoa1702417

Publication Type:

Journal Article

Authors:

Zeuzem, S; Foster, GR; Wang, S; et, al

Source:

N Engl J Med, Volume 378, Issue 4, p.354-369 (2018)

URL:

https://doi.org/10.1056/nejmoa1702417

Cited On:

External Third-party Web Link:

https://pubmed.ncbi.nlm.nih.gov/34333150/

Export Citation:
RIS Format
Top